Status of manganese contrast agents with clinical experience in myocardial imaging
| Contrast agent | Proposed clinical dose (μmol/kg) | Clinical trial/licensing status | Commercial availability | Barriers to clinical application | Currently recruiting or yet-to-report cardiac clinical trials |
| Chelated manganese: MnDPDP | 5 | Previously licensed in EU Phase III clinical trials complete | Previously available as Teslascan*, withdrawn due to lack of demand | No current clinical production | Manganese-enhanced MRI (MEMRI) of the myocardium (NCT03607669) |
| Non-chelated manganese: | |||||
| MnCl2† | 5 | Not licensed or undergoing clinical trial | Not available | Significant cardiotoxic potential in cardiac patients | None |
| EVP1001-1 | 1–10 | Phase II clinical trials complete | Not available | Currently undergoing further clinical trial Toxicity profile in cardiac patients not well established | Clinical Trial of MEMRI to assess peri-infarct Injury (NCT02933034) Efficacy of EVP1001-1 (see more) in the Assessment of myocardial viability in patients With cardiovascular disease (NCT01989195) |
*Marketing authorisation holder: GE Healthcare AS.
†No current plans for routine clinical use at time of writing due to toxicity profile.
EU, European Union; EVP1001-1, Eagle Vision Pharmaceutical; MnCl2, manganese chloride; MnDPDP, manganese dipyridoxyl diphosphate.